- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02371512
A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN (MATTERHORN)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Secondary or functional mitral regurgitation (MR) results from a geometrical distortion of a dysfunctional left ventricle leading to tethering of mitral valve leaflets by papillary muscle displacement, annular dilatation and/or reduced closing forces in a structurally normal mitral valve. It occurs in over 30% of patients with systolic heart failure. Despite optimal medical care it is associated with increased mortality and hospitalization rates leaving elimination of MR as the only therapeutic option. Nevertheless, traditionally, mitral valve surgery has been the therapy of choice in this setting.
As mitral valve surgery has so far been only investigated in retrospective single center registries, which have shown conflicting results. it has a class IIb recommendation, level of evidence C, in these patients without indication for coronary revascularization in the current guidelines of the European Society of Cardiology. In recent years percutaneous mitral valve repair with the MitraClip (PMVR) has evolved as an important therapeutic option in this type of patient with widespread use particularly in Europe, where the device was CE-marked in 2008. PMVR has been compared to mitral valve surgery (repair and replacement) in the randomized, controlled EVEREST II trial in patients with primary MR, which were good candidates for surgery, and was shown to be less effective than surgery in this context. However, no randomized, controlled data are available comparing PMVR and mitral valve surgery in patients with depressed left ventricular function and secondary MR, who have a considerably higher perioperative risk than the EVEREST II population. Like mitral valve surgery it has a class IIb, level of evidence C, recommendation in current guidelines.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Volker Rudolph, Prof. Dr. med
- Phone Number: 0049 221 47832401
- Email: volker.rudolph@uk-koeln.de
Study Contact Backup
- Name: Stephan Baldus, Prof. Dr. med.
- Phone Number: 0049 221 478-32511
- Email: stephan.baldus@uk-koeln.de
Study Locations
-
-
-
Cologne, Germany, 50935
- Recruiting
- Heart Center University of Cologne
-
Contact:
- Volker Rudolph, MD
- Phone Number: 478 32495
- Email: volker.rudolph@uk-koeln.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinically significant mitral regurgitation of primarily functional pathology
- Left Ventricular Ejection Fraction (LVEF) ≥20% determined by echocardiography
- High surgical risk as determined by Heart Team consensus
- Documented New York Heart Association Class II to Class IV heart failure, despite optimal standard of care therapy
- Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
Exclusion Criteria:
- Echocardiographic evaluation not available or not suitable for analysis at baseline
- Severe tricuspid regurgitation according to current guidelines5
- Other severe valve disorders requiring intervention according to current
- Coronary revascularization or cardiac resynchronization (CRT) device implantation within 1 month before the procedure
- Patient not amenable for mitral valve surgery/ percutaneous mitral valve reconstruction as judged by Heart Team
- Key information from patients (e.g. NYHA, MR grade) not available
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Percutaneous mitral valve repair (MitraClip system )
Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
|
Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
|
Active Comparator: Mitral valve surgery
Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
|
Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of death, rehospitalisation for heart failure, reintervention (repeat operation or repeat intervention), assist device implantation and stroke (whatever is first) 12 months post intervention; equivalently "freedom from event"
Time Frame: 12 months post intervention
|
Composite of death, rehospitalisation for heart failure, reintervention (repeat operation or repeat intervention), assist device implantation and stroke (whatever is first) 12 months post intervention; equivalently "freedom from event"
|
12 months post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence of grade 3 or 4 mitral regurgitation within 12 months post intervention
Time Frame: 12 months post intervention
|
Recurrence of grade 3 or 4 mitral regurgitation within 12 months post intervention
|
12 months post intervention
|
Change in 6 Minute Walk Test distance from baseline to 12 month post intervention (difference "12 months minus baseline
Time Frame: 12 months post intervention
|
Change in 6 Minute Walk Test distance from baseline to 12 month post intervention (difference "12 months minus baseline
|
12 months post intervention
|
Change in NYHA functional class from baseline to 12 months post intervention
Time Frame: 12 months post intervention
|
Change in NYHA functional class from baseline to 12 months post intervention
|
12 months post intervention
|
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score from baseline to 12 months post intervention
Time Frame: 12 months post intervention
|
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score from baseline to 12 months post intervention
|
12 months post intervention
|
Echocardiographic assessment of left ventricular remodelling
Time Frame: 12 months post intervention
|
12 months post intervention
|
|
Change in serum BNP from baseline to 12 months post intervention
Time Frame: 12 months post intervention
|
12 months post intervention
|
|
Length of stay ICU / hospital
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week. However, in some patients the hospital stay can be exceed this time frame, when complications occur.
|
Participants will be followed for the duration of hospital stay, an expected average of 1 week. However, in some patients the hospital stay can be exceed this time frame, when complications occur.
|
|
Number of patients in whom operative or interventional mitral valve repair can not be performed (need for mitral valve replacement)
Time Frame: 12 months post intervention
|
The primary therapeutic strategy should be a repair of the study.
For patients undergoing interventional therapy this endpoint is reached if the clip procedure is aborted and a mitral valve replacement is performed.
In patients undergoing surgery the endpoint is reached if the surgeon decides to implant a mitral valve during the same procedure.
|
12 months post intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Stephan Baldus, Prof. Dr. med., Herzzentrum Uniklinik Köln
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MATTERHORN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Valve Insufficiency
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Abbott Medical DevicesRecruitingCardiovascular Diseases | Heart Valve Diseases | Mitral Regurgitation | Mitral Valve Insufficiency | Valve Disease, Heart | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
4C Medical Technologies, Inc.RecruitingMitral Regurgitation | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Mitral IncompetenceUnited States
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Mitral Repair | Mitral Valve | Annuloplasty | Edwards CardiobandSwitzerland, Germany, Italy
-
Assistance Publique - Hôpitaux de ParisEuropean Association of Cardiovascular ImagingNot yet recruitingAortic Valve Stenosis | Aortic Valve Disease | Heart Valve Diseases | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Tricuspid Valve Insufficiency | Mitral Valve Disease | Tricuspid Valve Disease | Mitral Valve Insufficiency and... and other conditionsFrance
Clinical Trials on MitraClip system (Abbott Vascular, Menlo Park, USA)
-
Harbin Medical UniversityUnknownAcute Myocardial InfarctionChina
-
Xuanwu Hospital, BeijingNot yet recruitingStroke | Carotid Stenosis | Carotid Artery StentChina
-
The Hospital District of SatakuntaCompletedAcute Coronary SyndromeFinland
-
Assiut UniversityNot yet recruitingFemoropopliteal Occlusive DiseaseEgypt
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
The Hospital District of SatakuntaCompleted
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
Abbott Medical DevicesCompleted
-
Fogarty Clinical Research Inc.Abbott Medical Devices; Helen Kay Foundation; Northern Michigan Hospital Foundation...Unknown